Adjunctive Deep Touch Pressure for Comorbid Anxiety in Bipolar Disorder

2014 ◽  
Vol 20 (1) ◽  
pp. 71-77 ◽  
Author(s):  
LOUISA GRANDIN SYLVIA ◽  
LEAH W. SHESLER ◽  
ANDREW D. PECKHAM ◽  
TEMPLE GRANDIN ◽  
DAVID A. KAHN
2019 ◽  
Vol 7 (1) ◽  
Author(s):  
Maximilian Pilhatsch ◽  
Thomas J Stamm ◽  
Petra Stahl ◽  
Ute Lewitzka ◽  
Anne Berghöfer ◽  
...  

Abstract Background Symptoms of anxiety co-occur in a variety of disorders including in depressive episodes of bipolar disorder and in patients with thyrotoxicosis. Treatment of refractory bipolar disorder with supraphysiologic doses of levothyroxine (L-T4) has been shown to improve the phenotypic expression of the disorder and is associated with an increase of circulating thyroid hormones. However, it might be associated with somatic and mental adverse effects. Here we report the investigation of the influence of treatment with supraphysiologic doses of L-T4 on symptoms of anxiety in patients with refractory bipolar depression. Methods Post-hoc analysis from a 6-week, multi-center, randomized, double-blind, placebo-controlled study of the effects of supraphysiologic L-T4 treatment on anxiety symptoms in bipolar depression. Anxiety symptoms were measured weekly with the Hamilton anxiety/somatization factor (HASF) score of the Hamilton Depression Rating Scale (HAMD) and the State- and Trait Anxiety Inventory (STAI). Results Treatment of both groups was associated with a significant reduction in anxiety symptoms (p < 0.001) with no statistical difference between groups (LT-4: from 5.9 (SD = 2.0) at baseline to 3.7 (SD = 2.4) at study end; placebo: from 6.1 (SD = 2.4) at baseline to 4.4 (SD = 2.8) at study end; p = 0.717). Severity of anxiety at baseline did not show a statistically significant correlation to the antidepressive effect of treatment with supraphysiologic doses of L-T4 (p = 0.811). Gender did not show an influence on the reduction of anxiety symptoms (females: from 5.6 (SD = 1.7) at baseline to 3.5 (SD = 2.4) at study end; males: from 6.1 (SD = 2.3) at baseline to 4.0 (SD = 2.4) at study end; p = 0.877). Conclusions This study failed to detect a difference in change of anxiety between bipolar depressed patients treated with supraphysiologic doses of L-T4 or placebo. Comorbid anxiety symptoms should not be considered a limitation for the administration of supraphysiologic doses of L-T4 refractory bipolar depressed patients. Trial registration ClinicalTrials, ClinicalTrials.gov identifier: NCT01528839. Registered 2 June 2012—Retrospectively registered, https://clinicaltrials.gov/ct2/show/study/NCT01528839


2012 ◽  
Vol 36 (4) ◽  
pp. 482-508 ◽  
Author(s):  
K. K. Ellard ◽  
T. Deckersbach ◽  
L. G. Sylvia ◽  
A. A. Nierenberg ◽  
D. H. Barlow

Author(s):  
Kristen K. Ellard ◽  
Emily E. Bernstein ◽  
Andrew A. Nierenberg ◽  
Thilo Deckersbach

Bipolar disorder is a chronic and severe mental disorder characterized by affective lability and emotion dysregulation. In addition, it is associated with high rates of comorbidity, particularly with anxiety disorders. Approximately 90% of bipolar patients have been diagnosed with at least one comorbid anxiety disorder across the lifespan, with as many as two-thirds of patients meeting criteria for comorbid anxiety disorder at any given time. As such, transdiagnostic treatments that directly target emotion dysregulation in bipolar disorder are needed. In this chapter, we discuss evidence supporting an emotion dysregulation model of bipolar disorder and its roots in neuroticism. We then present a recent case of a patient with bipolar disorder with comorbid anxiety who received 18 sessions of treatment with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP).


2004 ◽  
Vol 65 (8) ◽  
pp. 1106-1113 ◽  
Author(s):  
Khrista R. Boylan ◽  
Peter J. Bieling ◽  
Michael Marriott ◽  
Helen Begin ◽  
L. Trevor Young ◽  
...  

2015 ◽  
Vol 69 (7) ◽  
pp. 552-556 ◽  
Author(s):  
Sadiye Visal Buturak ◽  
Orhan Murat Koçak

BJPsych Open ◽  
2018 ◽  
Vol 4 (3) ◽  
pp. 137-141 ◽  
Author(s):  
Kenneth R. Kaufman ◽  
Ronke Babalola ◽  
Miriam Campeas ◽  
Melissa Coluccio

Bipolar disorder with comorbid anxiety disorders frequently requires rational polypharmacy, including use of serotonergic psychotropics. These may result in adverse effects, influencing adherence, complicating treatment and confounding diagnoses. Serotonergic non-adherence is associated with discontinuation syndromes. In this complex case with an on/off/on/off design, both dose-dependent buspirone-induced gynecomastia and buspirone discontinuation syndrome with dental pain are reported. Clinicians and patients should consider these findings to maximise treatment adherence, minimise any unnecessary interventions and address unusual adverse effects. Since patients may not voluntarily disclose specific adverse effects and often do not acknowledge non-adherence, clinician-directed questions are required. This case further emphasises the importance of medication and symptom timelines to guide determination of causation for adverse effects. Although findings from this case cannot be generalised, they suggest the need for continued clinician and patient education, as well as the benefit from detailed case reports.Declaration of interestNone.


2005 ◽  
Vol 15 (4) ◽  
pp. 534-548 ◽  
Author(s):  
Daniel P. Dickstein ◽  
Brendan A. Rich ◽  
Anna B. Binstock ◽  
Anne G. Pradella ◽  
Kenneth E. Towbin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document